Table 5 Impact of potential prognostic factors on overall survival (univariate analysis)
At 6 months | At 12 months | P | |
|---|---|---|---|
RT regimen | |||
5 x 4 Gy (N = 142) | 87 | 68 | |
10 x 3 Gy (N = 142) | 84 | 73 | 0.64 |
Age | |||
≤63 years (N = 142) | 90 | 73 | |
≥64 years (N = 142) | 81 | 68 | 0.29 |
Gender | |||
Female (N = 138) | 87 | 74 | |
Male (N = 146) | 84 | 67 | 0.20 |
ECOG performance status | |||
1-2 (N = 226) | 92 | 77 | |
3-4 (N = 58) | 60 | 43 | <0.001 |
Type of primary tumor | |||
Breast cancer (N = 110) | 89 | 80 | |
Prostate cancer (N = 76) | 80 | 71 | |
Myeloma/lymphoma (N = 40) | 78 | 63 | |
Lung cancer (N = 12) | 83 | 56 | |
Other tumors (N = 46) | 93 | 50 | 0.11 |
Involved vertebrae (N) | |||
1-2 (N = 134) | 89 | 69 | |
≥3 (N = 150) | 83 | 71 | 0.42 |
Other bone metastases at the time of RT | |||
No (N = 140) | 91 | 72 | |
Yes (N = 144) | 80 | 68 | 0.10 |
Visceral metastases at the time of RT | |||
No (N = 264) | 88 | 73 | |
Yes (N = 20) | 50 | 35 | <0.001 |
Interval from tumor diagnosis to MESCC | |||
≤15 months (N = 80) | 80 | 63 | |
>15 months (N = 204) | 88 | 73 | 0.25 |
Ambulatory status before RT | |||
Not ambulatory (N = 30) | 63 | 50 | |
Ambulatory (N = 254) | 88 | 73 | 0.006 |
Time developing motor deficits before RT | |||
1-7 days (N = 20) | 85 | 73 | |
8-14 days (N = 68) | 79 | 59 | |
>14 days (N = 196) | 88 | 74 | 0.23 |